SPRED2 and breast cancer: Low mRNA expression level of SPRED2 also positively correlated with worse OS (Figure S1C) and RFS (Figure 1E,F and Figure S1D) in patients with ERα+ BC, and in those who have been treated with tamoxifen, suggesting that there could be a correlation between SPRED2 expression levels and tamoxifen resistance.